London
· Delayed Price · Currency is GBP · Price in GBX CRISM Therapeutics Statistics
Total Valuation
AIM:CRTX has a market cap or net worth of GBP 3.27 million. The enterprise value is 1.41 million.
| Market Cap | 3.27M |
| Enterprise Value | 1.41M |
Important Dates
The next estimated earnings date is Friday, May 9, 2025.
| Earnings Date | May 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
AIM:CRTX has 32.68 million shares outstanding. The number of shares has increased by 79.73% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 32.68M |
| Shares Change (YoY) | +79.73% |
| Shares Change (QoQ) | -30.27% |
| Owned by Insiders (%) | 0.54% |
| Owned by Institutions (%) | n/a |
| Float | 32.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | -105.41 |
| PB Ratio | 1.58 |
| P/TBV Ratio | 1.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.19 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.55 |
Financial Position
The company has a current ratio of 6.56
| Current Ratio | 6.56 |
| Quick Ratio | 6.56 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -62.45% and return on invested capital (ROIC) is -40.35%.
| Return on Equity (ROE) | -62.45% |
| Return on Assets (ROA) | -26.66% |
| Return on Invested Capital (ROIC) | -40.35% |
| Return on Capital Employed (ROCE) | -88.41% |
| Revenue Per Employee | -7,750 |
| Profits Per Employee | -1.88M |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -10.76% in the last 52 weeks. The beta is 0.15, so AIM:CRTX's price volatility has been lower than the market average.
| Beta (5Y) | 0.15 |
| 52-Week Price Change | -10.76% |
| 50-Day Moving Average | 8.09 |
| 200-Day Moving Average | 10.50 |
| Relative Strength Index (RSI) | 97.55 |
| Average Volume (20 Days) | 30,852 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AIM:CRTX had revenue of GBP -31,000 and -7.51 million in losses. Loss per share was -0.64.
| Revenue | -31,000 |
| Gross Profit | 1,000 |
| Operating Income | -1.83M |
| Pretax Income | -1.77M |
| Net Income | -7.51M |
| EBITDA | n/a |
| EBIT | -1.83M |
| Loss Per Share | -0.64 |
Balance Sheet
The company has 1.86 million in cash and n/a in debt, giving a net cash position of 1.86 million or 0.06 per share.
| Cash & Cash Equivalents | 1.86M |
| Total Debt | n/a |
| Net Cash | 1.86M |
| Net Cash Per Share | 0.06 |
| Equity (Book Value) | 2.07M |
| Book Value Per Share | 0.06 |
| Working Capital | 1.95M |
Cash Flow
In the last 12 months, operating cash flow was -2.56 million and capital expenditures 1,000, giving a free cash flow of -2.56 million.
| Operating Cash Flow | -2.56M |
| Capital Expenditures | 1,000 |
| Free Cash Flow | -2.56M |
| FCF Per Share | -0.08 |
Margins
| Gross Margin | n/a |
| Operating Margin | 5,903.25% |
| Pretax Margin | 5,709.44% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AIM:CRTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -79.73% |
| Shareholder Yield | -79.73% |
| Earnings Yield | -229.86% |
| FCF Yield | -78.46% |
Stock Splits
The last stock split was on May 31, 2024. It was a reverse split with a ratio of 0.00625.
| Last Split Date | May 31, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.00625 |
Scores
AIM:CRTX has an Altman Z-Score of 0.99. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.99 |
| Piotroski F-Score | n/a |